Atrial Fibrillation

  • 2008

    28 August 2008: Announcement no. 2, 2008: Zealand Pharma today announced that Dr. David H...

    Read More >

  • Product Pipeline

    Zealand's Pipeline comprises 1 compound in phase III, 2 compounds in phase II, 3 compounds ...

    Read More >

Atrial Fibrillation

Atrial fibrillation (AF) is the most common sustained arrhythmia in the Western patient population, affecting almost 10 percent of persons aged 75 or more. With the increased life expectancy and the improved treatment of patients with ischemic heart disease leading to longer survival of this patient population, the prevalence of AF is expected to reach epidemic proportions as the population ages.  AF is a disease that is most frequently found in patients with chronic cardiovascular disease (e.g. hypertensive, congestive, ischemic, and valvular heart disease). It is a serious disorder associated with an increased risk of stroke (3-5 fold increased risk), morbidity and mortality (1.5-1.9-fold increase).   AF is the leading cause of hospitalization for arrhythmia and it has serious impact on quality of life.  

Postoperative AF is common in patients undergoing cardiac surgery (G7 2006 Incidence: 630,000 operations). Risk of AF following valve surgeries is 1 in 2 and for coronary artery by-pass grafting it is 1 in 3. The consequences of post-operative AF are increased hospital length of stay and increased risk of post operative stroke.

 


To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.



Related links